Cogent Biosciences, Inc. (COGT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$29.58-6.07%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · COGT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -39.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
COGT — debt issuance
Dated 2026-08-10
Other Events. As previously disclosed, on May 6, 2022, Cogent Biosciences, Inc. (the “Company”) entered into a Sales Agreement with Guggenheim Securities, LLC (“Guggenheim Securities”), as amended by that certain Amendment No. 1 to Sales Agreement, dated November 7, 2025 (as amended, the “Sales Agreement”), pursuant to which the Company may offer and sell shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at any time and from time to time through or to Guggenhe…
Why it matters: IND filings would move two early drug programs toward human testing. Missed filing plans would slow this pipeline step.
Supportive ifCogent submits IND applications for both CGT1815 and CGT1145.
Worry ifCogent reports that either IND filing is delayed or that a program is paused.
Why it matters: Cogent has built its field team and signed a supply deal. Launch timing and supply updates will test its readiness.
Supportive ifAfter approval, Cogent reports a product launch. It confirms Hovione can supply the product.
Worry ifCogent reports a launch delay or a supply problem after an FDA approval.
Why it matters: These results will show how bezuclastinib performs for patients switching from avapritinib. Cogent has said results are due by year-end.
Watch forBy December 31, 2026, Cogent reports early results from the SUMMIT switch trial. These include patient response data.
Also watch forCogent reports no results by December 31, or reports that the study missed its stated goals.
Why it matters: The AdvSM filing would add a third bezuclastinib review. Its timing will show whether the wider launch plan stays on track.
Supportive ifThe FDA accepts the AdvSM application and sets a review date.
Worry ifThe FDA does not accept the application, or Cogent reports a filing delay.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$149 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $445 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,443 loss on $10,000 · 34.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.